Cholangiocarcinoma Pipeline, Clinical Trials Assessment, NDA Approvals 2023 (Updated) | QED Therapeutics, Taiho Oncology, Merck Sharp & Dohme Corp., EMD Serono/Merck, Eisai Inc., and others.

DelveInsight's, "Cholangiocarcinoma Pipeline Insight 2023" report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in the Cholangiocarcinoma pipeline landscape. It covers the Cholangiocarcinoma pipeline drug profiles, including Cholangiocarcinoma clinical trials and nonclinical stage products. It also covers the Cholangiocarcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

To explore more information on the latest breakthroughs in the Cholangiocarcinoma Pipeline treatment landscape of the report, click here @ Cholangiocarcinoma Pipeline Outlook- https://www.delveinsight.com/report-store/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Cholangiocarcinoma Pipeline Report
• DelveInsight's Cholangiocarcinoma Pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Cholangiocarcinoma.
• The leading Cholangiocarcinoma Companies include QED Therapeutics, Taiho Oncology, Merck Sharp & Dohme Corp., EMD Serono/Merck, Eisai Inc., 3D Medicines, PCI Biotech AS, Basilea Pharmaceutical, Newish Technology (Beijing) Co., Ltd., Bristol-Myers Squibb, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, AstraZeneca, Janssen Pharmaceuticals, Syndax Pharmaceuticals, Servier, CSPC Ouyi Pharmaceutical Co., Ltd., Eli Lilly and company, Elevation oncology, Senhwa Biosciences, Immunitor LLC, Chia Tai Tianqing Pharmaceutical, InnoCare Pharma, Genoscience Pharma, PureTech, Intensity therapeutics, Forma Therapeutics, TCR2 therapeutics, Elucida Oncology, NGM Biopharmaceuticals, Cellestia Biotech, Klus Pharma, PCI Biotech AS, Sirnaomics, Relay Therapeutics, Bold Therapeutics, Leap therapeutics, Boehringer Ingelheim, Elicio Therapeutics, and others
• Promising Cholangiocarcinoma Pipeline Therapies includes Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.
• In February 2022, HUTCHMED initiated a Phase Ib/II Study of HMPL-453 in Combination with Chemotherapy or Toripalimab for Advanced Solid Tumors, including intrahepatic cholangiocarcinoma in China. HMPL-453 is also being evaluated as monotherapy in Phase II clinical trials in China.
• In 2022, Basilea will continue its oncology activities to ensure project continuity and progression. For derazantinib, the company will continue the FIDES-01 study in intrahepatic cholangiocarcinoma (iCCA).
• In January 2022, US FDA cleared the Investigational New Drug (IND) application for KIN-3248 being developed by Kinnate Biopharma. KIN-3248 is a next-generation pan-FGFR inhibitor being developed for intrahepatic cholangiocarcinoma.

For further information, refer to the detailed Cholangiocarcinoma Unmet Needs, Cholangiocarcinoma Market Drivers, and Cholangiocarcinoma Market Barriers, click here for Cholangiocarcinoma Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Overview
Cholangiocarcinoma is an epithelial cell malignancy arising from varying locations within the biliary tree showing markers of cholangiocyte differentiation. The most contemporary classification based on anatomical location includes intrahepatic, perihilar, and distal cholangiocarcinoma. Many cases of cholangiocarcinoma arise de novo and do not have a specific risk factor, but there are a number of risk factors that have been identified, including primary hepatobiliary disease, genetic disorders, toxic exposures, and infections.

Request a sample and discover the recent advances in Cholangiocarcinoma Ongoing Clinical Trial Analysis and Medications, click here @ Cholangiocarcinoma Treatment Landscape- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Emerging Drugs

Pembrolizumab: Merck Sharp & dohme
Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. It is currently being evaluated in Phase III stage of development to treat biliary tract cancer.

E7090: Eisai
Discovered in-house by Eisai's Tsukuba Research Laboratories, E7090 is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against fibroblast growth factor receptors (FGFR) FGFR1, FGFR2, and FGFR3. Distinct from prior known FGFR inhibitors, E7090 has a basic structure that lacks the dimethoxyphenyl moiety, and in a kinetic interaction analysis study, it was observed that E7090 demonstrates antitumor effects due to inhibition of kinase activity with a binding mode (Type V) that exhibits rapid and potent binding as well as high selectivity to FGFR1. A Phase II clinical trial of E7090 is underway to evaluate the efficacy and safety in patients with cholangiocarcinoma with FGFR2 gene fusion. E7090 received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan.

ABC294640: RedHill Biopharma Limited
ABC294640 (Opaganib) is a first-in-class, proprietary sphingosine kinase-2 (SK2) selective inhibitor, administered orally, with anticancer, anti-inflammatory, and antiviral activities. Opaganib inhibits SK2, a lipid kinase that catalyzes the formation of the lipid signaling molecule sphingosine 1-phosphate (S1P). S1P promotes cancer growth, and proliferation and pathological inflammation, including TNFα signaling, and other inflammatory cytokine production. Specifically, by inhibiting the SK2 enzyme, opaganib blocks the synthesis of S1P, which regulates fundamental biological processes such as cell proliferation, migration, immune cell trafficking and angiogenesis, and is also involved in immune modulation and suppression of innate immune responses from T cells. Preliminary evidence suggests that because of its specificity for targeting SK2 rather than SK1, opaganib may have a better therapeutic ratio than nonspecific sphingosine kinase inhibitors or those targeting only SK1. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of cholangiocarcinoma.

TT-00420: TransThera Science
TT-00420 is a highly innovative, clinical-stage, spectrum-selective kinase inhibitor that exerts antitumor effects by targeting tumor cells and improving the tumor microenvironment. A large number of preclinical studies have found that TT-00420 has a promising inhibitory effect on triple-negative breast cancer, cholangiocarcinoma, and other malignant tumors. TT-00420 was granted Orphan Drug Designation and fast track designation by the FDA and is currently in the Phase II stage of its development for the treatment of cholangiocarcinoma.

KIN-3248: Kinnate Biopharma
KIN-3248 is a small molecule kinase inhibitor that targets cancer associated alterations in the FGFR2 and FGFR3 genes. KIN-3248 aims to address the primary driver alteration and clinically observed and predicted FGFR2/3 mutations. The company is currently evaluating the safety and tolerability of KIN-3248 in the Phase I stage of its development for the treatment of cholangiocarcinoma.

Dive deep into rich insights for drugs for Cholangiocarcinoma Market Drivers and Cholangiocarcinoma Market Barriers, click here @ Cholangiocarcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Cholangiocarcinoma Pipeline Therapeutics Assessment
• Coverage- Global
• Cholangiocarcinoma Companies- QED Therapeutics, Taiho Oncology, Merck Sharp & Dohme Corp., EMD Serono/Merck, Eisai Inc., 3D Medicines, PCI Biotech AS, Basilea Pharmaceutical, Newish Technology (Beijing) Co., Ltd., Bristol-Myers Squibb, Hutchison Medipharma Limited, Jiangsu HengRui Medicine, TransThera Sciences, RedHill Biopharma, AstraZeneca, Janssen Pharmaceuticals, Syndax Pharmaceuticals, Servier, CSPC Ouyi Pharmaceutical Co., Ltd., Eli Lilly and company, Elevation oncology, Senhwa Biosciences, Immunitor LLC, Chia Tai Tianqing Pharmaceutical, InnoCare Pharma, Genoscience Pharma, PureTech, Intensity therapeutics, Forma Therapeutics, TCR2 therapeutics, Elucida Oncology, NGM Biopharmaceuticals, Cellestia Biotech, Klus Pharma, PCI Biotech AS, Sirnaomics, Relay Therapeutics, Bold Therapeutics, Leap therapeutics, Boehringer Ingelheim, Elicio Therapeutics, and others
• Cholangiocarcinoma Pipeline Therapies- Derazantinib, VG161, SD 101, FT-2102, KIN-3248, RLY-4008, TYR-200, HMPL-453, Opaganib, XmAb®22841, STP705, Camrelizumab, Embrace™ Hydrogel Embolic System, CTX-009, and others.
• Cholangiocarcinoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Got Queries? Find out the related information on Cholangiocarcinoma Mergers and acquisitions, Cholangiocarcinoma Licensing Activities @ Cholangiocarcinoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/cholangiocarcinoma-cca-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Cholangiocarcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Mirvetuximab Soravtansine: ImmunoGen
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Gimatecan: Lee's Pharmaceuticals
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I/II)
13. TX200-TR101: Sangamo therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Cholangiocarcinoma Key Companies
17. Cholangiocarcinoma Key Products
18. Cholangiocarcinoma- Unmet Needs
19. Cholangiocarcinoma- Market Drivers and Barriers
20. Cholangiocarcinoma- Future Perspectives and Conclusion
21. Cholangiocarcinoma Analyst Views
22. Cholangiocarcinoma Key Companies
23. Appendix

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.